Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Verrica Pharmaceuticals Inc. (NYSE: VRCA) violated federal securities laws. Verrica is a clinical stage medical dermatology company that develops and commercializes dermatological treatments.
If you suffered a loss as a result of Verrica's misconduct, click here.
Verrica Pharmaceuticals Inc. (VRCA) Announces Receipt of FDA Letter
On June 29, 2020, Verrica disclosed that on June 24, 2020, the Company had received a letter from the U.S. Food & Drug Administration ("FDA") as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for VP-102, the Company's lead product candidate for the treatment of molluscum contagiosum. The letter stated that there were deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. Verrica then noted that the FDA requested information "related to a potential safety issue with the applicator that could arise if the instructions for use were not properly followed." On this news, Verrica's stock price fell 28% over the next two trading days to close at $10.16 per share on July 1, 2020.
Verrica Pharmaceuticals Inc. (VRCA) Shareholders Have Legal Options
Want to be notified if a class action on behalf of Verrica settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.